Arialys Therapeutics' precision medicine has shown preclinical potential to address the underlying cause of anti-NMDA ...

Recent findings have also identified anti-NMDA receptor autoantibodies in other neurological and psychiatric diseases such as schizophrenia, depression, bipolar disorder, and dementia.

c-Fos in Alzheimer’s Disease In AD, c-Fos expression is aberrantly elevated, correlating with amyloid-β (Aβ) accumulation and cognitive impairment. Aβ stabilizes c-Fos via O-GlcNAcylation ...

Anti-NMDA receptor encephalitis (ANRE) is a rare, ... and dementia. Arialys is planning clinical assessment of ART5803 in anti-NMDA receptor autoantibody-positive psychosis patients.

The startup is one of several that have recently raised mega rounds of financing to support programs in the clinic or ...

The company also acquired the rights to Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ketamine that has shown indications of having fewer side effects, working ...

Sage had 338 full-time employees, all of whom will be laid off effective Aug. 22. The layoffs were announced a few weeks ...

New data reveals more than 7 million Americans are currently living with Alzheimer’s – a first in U.S. history. Experts warn this number is projected to nearly double, reaching an estimated 14 ...

A new way of thinking about Alzheimer's disease has yielded a discovery that could be the key to stopping the cognitive decline seen in Alzheimer's and other neurodegenerative diseases, including ...

The annual Alzheimer's disease drug development pipeline report is led by Dr. Jeffrey Cummings, a renowned Alzheimer's clinician-scientist. The report reviews the status and associated trends ...

Alzheimer's disease affects millions of people around the world and occurs when abnormal proteins build up in the brain, leading to the death of brain cells and declines in cognitive function and ...